Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of GLP-1 (Glucagon-Like Peptide-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes

A technology for type 2 diabetes and macrovascular, which is applied in the field of GLP-1 for the preparation of drugs for preventing and treating macrovascular complications of type 2 diabetes, and can solve problems such as inability to effectively cure diabetes and cardiovascular complications.

Inactive Publication Date: 2013-09-11
SOUTHERN MEDICAL UNIVERSITY
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There are many drugs currently used for the treatment of diabetic cardiovascular complications, but their main functions are to lower blood lipids, inhibit platelet aggregation and promote vasodilation to prevent further deterioration of the disease. These drugs cannot effectively cure diabetic cardiovascular complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of GLP-1 (Glucagon-Like Peptide-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes
  • Use of GLP-1 (Glucagon-Like Peptide-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes
  • Use of GLP-1 (Glucagon-Like Peptide-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Construction of endothelial cell injury model of type 2 diabetes

[0016] In this example, high glucose and high insulin are used to stimulate vascular endothelial cells, simulating the environment of high glucose and high insulin in type 2 diabetes, and constructing an endothelial cell injury model.

[0017] Experimental animals and cells:

[0018] Healthy adult male / female SD (Sprague-Dawley) rats were purchased from the Experimental Animal Center of Southern Medical University, and rat aortic endothelial cells were isolated from the thoracic aorta of healthy adult male / female SD rats.

[0019] experimental method:

[0020] Healthy adult male / female SD rats were killed by cervical dislocation, the rat thoracic aorta was separated, the fatty tissue around the blood vessels was peeled off, the intima was everted, the two ends of the blood vessels were ligated with a ligature, and collagenase type Ⅰ (2g / L ) digested at 37°C for 45 minutes, cut blood vessels ...

Embodiment 2

[0040] Example 2: Effect of GLP-1 on apoptosis of rat aortic endothelial cells induced by high glucose and high insulin

[0041] In this example, on the basis of the diabetic vascular cell injury model constructed in Example 1, the protective effect of GLP-1 on diabetic vascular endothelial cell injury is systematically studied, and its mechanism is revealed. The method provides a basis.

[0042] Experimental animals and cells:

[0043] Healthy adult male / female SD rats were purchased from the Experimental Animal Center of Southern Medical University, and rat aortic endothelial cells were isolated from the thoracic aorta of healthy adult male / female SD rats.

[0044] experimental method:

[0045] The GLP-1 used in this experiment is GLP-1 (7-36), which was purchased from Shanghai Tricaptide Biotechnology Co., Ltd.

[0046] Rat aortic endothelial cells were plated, and when the cells grew to 85% of the bottom of the dish, the cells were starved overnight with sugar-free and ...

Embodiment 3

[0074] Embodiment three: pharmaceutical preparation

[0075] Natural GLP-1 or GLP-1 analogs are used as active ingredients, formulated in pharmaceutically acceptable excipients, carriers or diluents, adjusted to the filling concentration, filtered and sterilized, depyrogenated, filled, and prepared Injection, and further can be made into freeze-dried powder injection. For the relevant process, reference can be made to the conventional pharmaceutical process in this field.

[0076] These pharmaceutical preparations can be clinically used for intravenous infusion or subcutaneous injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides use of glucagon-like peptide-1 (GLP-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes. The experiments show that GLP-1 has the anti-apoptosis effect by inhibiting the JNK (Jun N-terminal Kinase) signal paths of aortic endothelial cells of mice, increasing expression of Bc1-2 and inhibiting the activity of caspase-3. The effect is probably completed by promoting ROS (Reactive Oxygen Species) in scavenger-cells to exert anti-oxidative damage effect. GLP-1 in vitro and in vivo can remarkably improve degree of injury of great vessels of mice with type 2 diabetes. Therefore, GLP-1 can be used for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes. The invention further provides a pharmaceutical composition for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes.

Description

technical field [0001] The invention belongs to the field of prevention and treatment of diabetic complications, and relates to the new use of GLP-1 (glucagon-like peptide-1), in particular to the use of GLP-1 in the preparation of drugs for preventing and treating macrovascular complications of type 2 diabetes . Background technique [0002] Diabetes refers to a type of disease in which the absolute or relative lack of insulin in the blood leads to excessive blood sugar, which in turn causes metabolic disorders such as fat and protein. Improperly controlled diabetes has many complications, such as infection, heart disease, cerebrovascular disease, renal failure, blindness, and lower extremity gangrene. These complications seriously affect the quality of life of patients and even threaten their lives. Among them, cardiovascular complications are the main cause of death in diabetic patients. The main pathological basis of diabetic cardiovascular complications is damage to s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/26A61K38/22A61P3/10A61P9/00
Inventor 惠宏襄唐永明赵小宁马丁何殿殿李妍
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com